Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320
Future Medicinal Chemistry · 2023
DOI: 10.4155/fmc-2023-0114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2023. Verfasst von Li Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, PR China. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Antineoplastic Agents, Lysine, Glutaminase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Aim
A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays.
Results
AC16 exhibited robust GLS1 inhibitory activity, antiproliferative effect in vitro, good plasma stability and potential covalent addition with GLS1 K320.
Conclusion
This study opens a novel avenue for the design of robust irreversible GLS1 inhibitors targeting the allosteric site K320.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, PR China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
- Department of Chemistry, Lomonosov Moscow State University (MSU), Moscow, 119991, Russia.
ORCID-Profile: Alexander V Finko, Huidan Huang
Zitieren
APA
Zhu, L., Chang, X., Zhang, S., Bai, X., Finko, A. V., Xu, X., Bian, J., Liu, X., & Huang, H. (2023). Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2023-0114
Vancouver
Zhu L, Chang X, Zhang S, Bai X, Finko AV, Xu X, et al. Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320. Future Medicinal Chemistry. 2023. doi:10.4155/fmc-2023-0114
BibTeX
@article{Zhu2023,
author = {Zhu, Li and Chang, Xiujin and Zhang, Shengpeng and Bai, Xiumei and Finko, Alexander V and Xu, Xi and Bian, Jinlei and Liu, Xiaoping and Huang, Huidan},
title = {Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320},
journal = {Future Medicinal Chemistry},
year = {2023},
doi = {10.4155/fmc-2023-0114}
}
EUVIMED